Canada markets closed
  • S&P/TSX

    21,077.35
    -85.30 (-0.40%)
     
  • S&P 500

    4,701.21
    +14.46 (+0.31%)
     
  • DOW

    35,754.75
    +35.32 (+0.10%)
     
  • CAD/USD

    0.7901
    -0.0005 (-0.06%)
     
  • CRUDE OIL

    73.08
    +0.72 (+1.00%)
     
  • BTC-CAD

    62,913.56
    -913.75 (-1.43%)
     
  • CMC Crypto 200

    1,301.04
    -4.07 (-0.31%)
     
  • GOLD FUTURES

    1,783.80
    -1.70 (-0.10%)
     
  • RUSSELL 2000

    2,271.71
    +17.92 (+0.80%)
     
  • 10-Yr Bond

    1.5090
    +0.0290 (+1.96%)
     
  • NASDAQ futures

    16,406.50
    +14.25 (+0.09%)
     
  • VOLATILITY

    19.90
    -1.99 (-9.09%)
     
  • FTSE

    7,337.05
    -2.85 (-0.04%)
     
  • NIKKEI 225

    28,855.29
    -5.33 (-0.02%)
     
  • CAD/EUR

    0.6969
    +0.0002 (+0.03%)
     

Roper Technologies to Divest CIVCO Radiotherapy

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

SARASOTA, Fla., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Roper Technologies, Inc. (NYSE: ROP), a leading diversified technology company, today announced that it has reached a definitive agreement to sell its CIVCO Radiotherapy business to an affiliate of Blue Wolf Capital Partners LLC, a private equity firm, in an all-cash transaction valued at $120 million. Roper will retain its CIVCO Medical Solutions business, which will continue to operate independently.

Roper retained William Blair as a financial advisor in connection with this transaction. Roper expects the transaction to close in the fourth quarter, subject to customary closing conditions.

About Roper Technologies

Roper Technologies is a constituent of the S&P 500, Fortune 500, and the Russell 1000 indices. Roper operates businesses that design and develop software (both license and software-as-a-service) and engineered products and solutions for a variety of niche end markets. Additional information about Roper is available on the Company’s website at www.ropertech.com.

About CIVCO Radiotherapy

CIVCO Radiotherapy has over 35 years’ experience developing, manufacturing, and providing high-quality, innovative, patient-centric solutions in radiotherapy. These solutions include advanced patient immobilization and positioning hardware and consumables, fiducial markers, couchtops and overlays, software, patient care products, and advanced 6DOF robotic patient positioning. Corporate information is available at www.CivcoRT.com.

About Blue Wolf Capital Partners

Blue Wolf Capital Partners LLC is a private equity firm that specializes in control investments in middle market companies. Leading by experience, and with a commitment to excellence, Blue Wolf transforms companies strategically, operationally, and collaboratively. Blue Wolf manages challenging situations and complex relationships between business, customers, employees, unions, and regulators to build value for stakeholders. For additional information, please visit www.bluewolfcapital.com.

The information provided in this press release contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements may include, among others, statements regarding operating results, the success of our internal operating plans, and the prospects for newly acquired businesses to be integrated and contribute to future growth, profit and cash flow expectations. Forward-looking statements may be indicated by words or phrases such as "anticipate," "estimate," "plans," "expects," "projects," "should," "will," "believes," "intends" and similar words and phrases. These statements reflect management's current beliefs and are not guarantees of future performance. They involve risks and uncertainties that could cause actual results to differ materially from those contained in any forward-looking statement. Such risks and uncertainties include any ongoing impacts of the COVID-19 pandemic on our business, operations, financial results and liquidity, which will depend on numerous evolving factors which we cannot accurately predict or assess, including: the duration and scope of the pandemic, new variants of the virus and the distribution and efficacy of vaccines; any negative impact on global and regional markets, economies and economic activity; actions governments, businesses and individuals take in response to the pandemic; the effects of the pandemic, including all of the foregoing, on our customers, suppliers, and business partners, and how quickly economies and demand for our products and services recover after the pandemic subsides. Such risks and uncertainties also include our ability to identify and complete acquisitions consistent with our business strategies, integrate acquisitions that have been completed, realize expected benefits and synergies from, and manage other risks associated with, the newly acquired businesses. We also face other general risks, including our ability to realize cost savings from our operating initiatives, general economic conditions and the conditions of the specific markets in which we operate, changes in foreign exchange rates, difficulties associated with exports, risks associated with our international operations, cybersecurity and data privacy risks, including litigation resulting therefrom, risks related to political instability, armed hostilities, incidents of terrorism, public health crises (such as the COVID-19 pandemic) or natural disasters, increased product liability and insurance costs, increased warranty exposure, future competition, changes in the supply of, or price for, parts and components, environmental compliance costs and liabilities, risks and cost associated with litigation, including asbestos related litigation, potential write-offs of our substantial intangible assets, and risks associated with obtaining governmental approvals and maintaining regulatory compliance for new and existing products. Important risks may be discussed in current and subsequent filings with the SEC. You should not place undue reliance on any forward-looking statements. These statements speak only as of the date they are made, and we undertake no obligation to update publicly any of them in light of new information or future events.

Contact Information:
Investor Relations
941-556-2601
investor-relations@ropertech.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting